Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team

UMMS Affiliation

Department of Pediatrics; Program in Molecular Medicine

Publication Date


Document Type



Adult; Anti-HIV Agents; Cohort Studies; Female; Follow-Up Studies; HIV Infections; *HIV-1; Humans; Infant; Infant, Newborn; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; effects


Immunology and Infectious Disease | Pediatrics


The safety, toxicity, and pharmacokinetics of intrapartum and early newborn nevirapine were evaluated in 17 human immunodeficiency virus type 1-infected women in labor and their newborns. No adverse effects of nevirapine were noted in any study mothers or infants. Following maternal dosing with 200 mg during labor, concentrations exceeding 100 ng/mL (10 times the in vitro IC50) were achieved in the newborns. Nevirapine elimination was prolonged in both mothers and infants, with median half-lives ranging from 36.8 to 65.7 h. Administration of 200 mg orally to the mothers in labor and of a single 2-mg/kg oral dose to the infants at 48-72 h after birth maintained serum concentrations in the infants > 100 ng/mL through 7 days of life.


J Infect Dis. 1998 Aug;178(2):368-74.

Journal/Book/Conference Title

The Journal of infectious diseases

Related Resources

Link to Article in PubMed

PubMed ID